Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CHOLESTYRAMINE vs ADDERALL 30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cholestyramine is a bile acid sequestrant that binds bile acids in the intestine, forming an insoluble complex that is excreted in feces. This reduces enterohepatic circulation of bile acids, leading to increased conversion of cholesterol to bile acids in the liver and decreased serum low-density lipoprotein (LDL) cholesterol levels.
Adderall contains mixed amphetamine salts that increase synaptic levels of dopamine and norepinephrine by inhibiting their reuptake and promoting release from presynaptic terminals.
Primary hypercholesterolemia (Type IIa hyperlipoproteinemia),Pruritus associated with partial biliary obstruction and primary biliary cirrhosis,Pseudomembranous colitis (Clostridioides difficile infection)-associated diarrhea (adjunctive),Diarrhea associated with bile acid malabsorption,Eczema (off-label),Hyperoxaluria (off-label)
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy
4 g orally once or twice daily, titrated up to 24 g/day divided into 2-6 doses; usual maintenance dose 8-16 g/day
Initial: 5 mg orally once or twice daily; increase by 5 mg increments weekly; usual maintenance: 20-30 mg daily in divided doses; maximum: 40 mg/day
Not applicable; cholestyramine is not absorbed and does not have a systemic half-life. Its clinical effect is related to gastrointestinal transit time.
Terminal elimination half-life: d-amphetamine 10-13 hours, l-amphetamine 13-15 hours; in adults (children: 6-8 hours). The longer half-life allows for once-daily dosing.
Cholestyramine is not absorbed systemically; it acts locally in the gastrointestinal tract and is excreted unchanged in feces.
Primarily hepatic via CYP2D6, with minor contributions from CYP1A2, CYP2B6, and CYP3A4.
Cholestyramine is not absorbed systemically; it remains in the gastrointestinal tract and is excreted unchanged in feces. No renal or biliary elimination occurs.
Approximately 30-40% of a dose is excreted unchanged in urine; the remainder is metabolized primarily by oxidative deamination and aromatic hydroxylation. Biliary/fecal elimination accounts for less than 5%.
Not applicable; cholestyramine is not absorbed and does not bind to plasma proteins.
Approximately 20-25% bound to plasma proteins, mainly albumin and alpha-1-acid glycoprotein.
Not applicable; due to lack of systemic absorption, Vd is essentially zero.
Vd: 3-4 L/kg (approximately 210-280 L for a 70 kg adult). This indicates extensive tissue distribution and penetration into the central nervous system.
Oral: <0.1% (negligible systemic absorption); cholestyramine acts locally in the gastrointestinal tract.
Oral immediate-release: approximately 75-100%; oral extended-release: approximately 94% relative to immediate-release. Food does not significantly affect absorption but may delay peak concentration.
No dosage adjustment required for renal impairment; caution in patients with severe renal disease due to risk of hyperchloremic metabolic acidosis
GFR 30-89 m L/min: no adjustment; GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: avoid use
Use with caution in cirrhosis or cholestatic disorders; no specific Child-Pugh guidelines; monitor for increased bleeding risk due to vitamin K malabsorption
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use
Initial 240 mg/kg/day (approximately 0.625 g/kg/day) divided into 2-3 doses, titrated based on response; maximum 8 g/day
Children 3-5 years: initial 2.5 mg orally once daily; increase by 2.5 mg weekly; usual range 2.5-20 mg/day. Children ≥6 years: initial 5 mg once or twice daily; increase by 5 mg weekly; usual range 5-40 mg/day in divided doses
Start at low end of dosing range (4 g/day) due to increased risk of constipation and fecal impaction; monitor for electrolyte disturbances and drug interactions
Initiate at 2.5 mg orally once or twice daily; titrate slowly; monitor for cardiovascular effects, insomnia, and weight loss
No FDA black box warning.
Amphetamines have a high potential for abuse and dependence. Misuse may cause sudden death or serious cardiovascular events.
May reduce absorption of fat-soluble vitamins (A, D, E, K) and folic acid; supplementation may be required.,May impair absorption of other medications (e.g., digoxin, warfarin, thyroid hormones); administer at least 4-6 hours before or after cholestyramine.,May cause hyperchloremic metabolic acidosis, especially in pediatric patients.,May exacerbate hemorrhoids due to constipation.,Use with caution in patients with phenylketonuria (contains aspartame in some formulations).
Risk of serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities,Increased blood pressure and heart rate,Psychiatric adverse events including exacerbation of pre-existing psychosis, mania, or aggressive behavior,Serotonin syndrome risk when co-administered with serotonergic drugs,Long-term suppression of growth in children,Seizure risk in patients with history of seizures,Peripheral vasculopathy including Raynaud's phenomenon,Visual disturbances due to mydriasis
Complete biliary obstruction (unable to excrete bile into intestine),Hypersensitivity to cholestyramine or any component,Phenylketonuria (if product contains aspartame)
Advanced arteriosclerosis,Symptomatic cardiovascular disease,Moderate to severe hypertension,Hyperthyroidism,Known hypersensitivity to amphetamines,Agitated states,History of drug abuse,During or within 14 days of MAO inhibitor use,Glaucoma
Cholestyramine may interfere with absorption of fat-soluble vitamins (A, D, E, K). Long-term use may require supplementation. Administer with meals to bind bile acids. High-fiber foods may help counteract constipation. Avoid taking cholestyramine close to other medications or foods that require optimal absorption.
Avoid high-fat meals as they delay absorption; avoid acidic foods (e.g., citrus) and vitamin C supplements within 1 hour of dosing as they decrease absorption; limit caffeine and other stimulants to avoid additive cardiovascular effects.
Cholestyramine is not absorbed systemically; therefore, direct fetal exposure is negligible. No teratogenic effects have been reported in animal studies or human case reports. However, due to potential maternal fat-soluble vitamin deficiency (A, D, E, K) caused by the drug, indirect fetal risk exists, especially in the first trimester for neural tube defects (vitamin A) and second/third trimester for coagulation (vitamin K). Use only if clearly needed and monitor maternal vitamin levels.
Pregnancy category C. First trimester: No well-controlled studies, but potential for congenital malformations not definitively established. Second and third trimesters: Increased risk of premature delivery, low birth weight, and neonatal withdrawal symptoms (e.g., dysphoria, agitation, lassitude). Chronic use may lead to neonatal toxicity.
Cholestyramine is not excreted into breast milk due to negligible systemic absorption. It is considered compatible with breastfeeding, as no adverse effects on the nursing infant have been reported. M/P ratio is not applicable. Monitor infant for signs of vitamin deficiency if mother uses high doses long-term.
Excreted in breast milk. M/P ratio unknown. Potential for stimulant effects in infant (e.g., irritability, poor feeding, insomnia). Caution advised; consider alternative feeding methods.
No dose adjustment is needed for pregnancy because cholestyramine is not absorbed systemically. However, consider increasing the dose if concurrent vitamin supplementation is used, as cholestyramine may bind and reduce absorption of fat-soluble vitamins. Administer vitamins at least 1 hour before or 4-6 hours after cholestyramine. Monitor for adequate therapeutic effect; dose may be adjusted based on clinical response (e.g., pruritus or diarrhea control).
No established dosing guidelines. Due to increased plasma volume and clearance, dose may need titration to clinical effect, but avoid supratherapeutic doses. Use lowest effective dose.
Cholestyramine is a bile acid sequestrant used to lower LDL cholesterol by binding bile acids in the intestine, increasing their fecal excretion, and upregulating hepatic LDL receptors. It is also used for pruritus associated with cholestasis and for diarrhea due to bile acid malabsorption. Administer other medications at least 1 hour before or 4-6 hours after cholestyramine, as it can impair absorption of many drugs (e.g., warfarin, digoxin, thyroid hormones). Monitor for constipation, which is common and can be severe; increase fiber and fluid intake. Cholestyramine can cause hypertriglyceridemia; check triglycerides before and during therapy. It may reduce absorption of fat-soluble vitamins (A, D, E, K); consider supplementation with long-term use.
For ADHD: start low, go slow; monitor weight and height in children; avoid late doses to prevent insomnia; check for abuse/diversion; screen for bipolar disorder and hypertension; consider urine drug screen before prescribing; avoid MAOIs within 14 days; use with caution in seizure disorders and glaucoma.
Take this medication exactly as prescribed, usually 2-4 times daily with meals or at bedtime.,Mix the powder with at least 4-8 ounces of water, fruit juice, or non-carbonated beverage; stir well and drink immediately. Do not swallow dry powder.,Do not take other medications or supplements within 1 hour before or 4-6 hours after taking cholestyramine, as it can prevent their absorption.,Increase fluid and dietary fiber intake to help prevent constipation. Notify your doctor if constipation becomes severe or if you have stomach pain.,Inform your doctor if you develop unusual bleeding or bruising, which may indicate vitamin K deficiency.,Cholestyramine may increase blood triglyceride levels; your doctor will monitor your blood lipid profile.,If you are pregnant, planning to become pregnant, or breastfeeding, discuss risks and benefits with your doctor.,Store at room temperature, away from moisture and heat.
Take exactly as prescribed; do not crush or chew capsules.,Take the first dose upon waking; avoid afternoon/evening doses.,May cause insomnia, loss of appetite, or nervousness.,Do not drink alcohol while taking this medication.,Report chest pain, palpitations, shortness of breath, or mood changes.,Store securely; do not share medication with others.,Regular blood pressure and heart rate monitoring is necessary.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CHOLESTYRAMINE vs ADDERALL 30, answered by our medical review team.
CHOLESTYRAMINE is a Bile Acid Sequestrant that works by Cholestyramine is a bile acid sequestrant that binds bile acids in the intestine, forming an insoluble complex that is excreted in feces. This reduces enterohepatic circulation of bile acids, leading to increased conversion of cholesterol to bile acids in the liver and decreased serum low-density lipoprotein (LDL) cholesterol levels.. ADDERALL 30 is a CNS Stimulant that works by Adderall contains mixed amphetamine salts that increase synaptic levels of dopamine and norepinephrine by inhibiting their reuptake and promoting release from presynaptic terminals.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CHOLESTYRAMINE and ADDERALL 30 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CHOLESTYRAMINE is: 4 g orally once or twice daily, titrated up to 24 g/day divided into 2-6 doses; usual maintenance dose 8-16 g/day. The standard adult dose of ADDERALL 30 is: Initial: 5 mg orally once or twice daily; increase by 5 mg increments weekly; usual maintenance: 20-30 mg daily in divided doses; maximum: 40 mg/day. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CHOLESTYRAMINE and ADDERALL 30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CHOLESTYRAMINE is classified as Category C. Cholestyramine is not absorbed systemically; therefore, direct fetal exposure is negligible. No teratogenic effects have been reported in animal studies or human case reports. Howe. ADDERALL 30 is classified as Category C. Pregnancy category C. First trimester: No well-controlled studies, but potential for congenital malformations not definitively established. Second and third trimesters: Increased r. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.